Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

36.27 +1.16 (+3.32%)
Streaming Delayed Price Updated: 1:38 PM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday ↗
The company announced a stock sale to help fund operations. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Stocks Open Higher; US Trade Deficit Widens In April ↗
U.S. stocks traded mostly higher this morning, with Nasdaq Composite gaining over 75 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.05% to 33,590.92 while the NASDAQ... 
Via Benzinga
News headline image
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET 
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End ↗
These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch. 
Via InvestorPlace
News headline image
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
US Stocks Mixed; McDonald's Earnings Top Estimates ↗
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 30 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.09% to 33,685.72 while the NASDAQ rose 0.29%... 
Via Benzinga
News headline image
Why Applied UV Shares Are Trading Higher By 46%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers FOXO Technologies Inc. (NYSE: FOXO) shares jumped 109% to $1.07. Akanda Corp. (NASDAQ: AKAN) rose 59% to $0.4459 after jumping 47% on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Dip ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Newly Listed NewAmsterdam Pharma Touts Encouraging Data From High Cholesterol Treatment ↗
 
Via Benzinga
News headline image
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.